CEPI FA2 Preclinical Development Award
Funds organizations conducting preclinical vaccine development for CEPI priority pathogens and Disease X exemplars through CEPI's Innovations call.
CEPI (Coalition for Epidemic Preparedness Innovations), a non-profit international association headquartered in Oslo, administers this grant under its Innovations to Prepare for Future Epidemics and Pandemics call — specifically Focus Area 2, which targets vaccine candidates for priority pathogens and viral families. Awards of up to US $5 million fund preclinical proof-of-concept work, including IND-enabling studies, CMC development, analytical methods, process optimization, scale-up, and formulation. No co-funding or matching requirement is stated in the source. Duration is not explicitly stated for this award tier (only the up-to-$5M cap is given). Eligible applicants include for-profit companies, nonprofits, universities, research organizations, and government bodies from any country. Global South applicants are particularly encouraged to apply. For Lassa Fever specifically, preference is given to groups based in Lassa Fever endemic regions in West Africa, or with plans to conduct clinical evaluation in those areas. There is no citizenship requirement or company-age restriction stated. Applications are submitted quarterly on a rolling basis by email to innovations.cfp@cepi.net. The call text covers a window from 24 October 2023 through 13 April 2026, with deadlines at 23:59 CET on each quarterly date. CEPI strongly encourages applicants to contact innovations.cfp@cepi.net before submitting to confirm alignment with current portfolio priorities. Proposals are evaluated by CEPI's scientific and programmatic reviewers against fit with CEPI's strategic objectives. Key caveats: the last stated deadline in the published call text was 13 April 2026, and no successor call window has been announced as of June 2026. Applicants should contact CEPI directly to confirm whether the call is still accepting proposals or a new round is planned. The total funding pool for this call is not stated in the source.
Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.
Funds organizations conducting clinical trials of vaccine candidates against CEPI priority pathogens and viral families through CEPI's Innovations Call for Proposals.
Funds organizations designing and early-stage testing of new vaccine candidates against CEPI priority pathogens and Disease X viral families, with awards up to $1M over 18 months.
Funds organizations conducting preclinical vaccine development for CEPI priority pathogens and Disease X exemplars through CEPI's Innovations call.